Background: The impact of switching antiretroviral therapy (ART) regimen for dyslipidemia management in HIV-infected (HIV+) patients has not been reported in Chile.
Aim: To assess effectiveness and safety at 12 months after switching to raltegravir-based regimen for dyslipidemia management.
Methods: Retrospective cohort of HIV+ patients receiving ART at Arriaran Foundation, with dyslipidemia switched to raltegravir-based regimen for lipid management.
Results: 73 patients were included, receiving ART based in nonnucleoside reverse transcriptase inhibitor (NNRTI; 50,7%) or protease inhibitor (PI; 49,3%), with mixed dyslipidemia (42,5%) or isolated hypertriglyceridemia (57,5%). At baseline, median total cholesterol (TC) and triglycerides (TG) were 228 mg/dl and 420 mg/dl, respectively; undetectable viral load (VL) was present in 94,5% of patients. Backbone ART was switched in 58,4% and lipid-lowering therapy was used by 89,1% of them. At 12 months, there was a significant decrease in TG (-43,6%) and TC (-19,3%). No cases of virologic failure were observed, although 10,9% of patients had detectable VL at 12 months, mostly transient.
Conclusions: Switching ART to raltegravir-based regimen in dyslipidemic patients receiving NNRTI or PI is associated with a significative decrease in TG and TC at 12 months. This strategy is safe, but VL can be increased temporarily.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/S0716-10182019000400490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of integrase strand transfer inhibitor resistance in people living with HIV and virological failure.
J Chin Med Assoc
November 2024
Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
Article Synopsis
- This study investigates the resistance profiles of integrase strand transfer inhibitors (INSTIs) in patients from southern Taiwan who experienced failure in antiretroviral therapy (ART), particularly focusing on those previously treated with highly active ART (HAART).
- It analyzes data from patients who failed an INSTI-containing regimen between 2009 and 2022, with genotypic drug resistance tested against established guidelines, revealing insights into mutations associated with treatment failure.
- Among 21 patients who failed INSTI therapy, 40% showed INSTI drug resistance, with specific mutations identified, highlighting the challenges in treating individuals with resistant strains in a treatment-experienced population.
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Lancet HIV
June 2024
Service de virologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
Background: Due to the low number of individuals with HIV-2, no randomised trials of HIV-2 treatment have ever been done. We hypothesised that a non-comparative study describing the outcomes of several antiretroviral therapy (ART) regimens in parallel groups would improve understanding of how differences between HIV-1 and HIV-2 might lead to different therapeutic approaches.
Methods: This pilot, phase 2, non-comparative, open-label, randomised controlled trial was done in Burkina Faso, Côte d'Ivoire, Senegal, and Togo.
Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens.
AIDS
March 2024
Research Department, Children's Diagnostic & Treatment Center, Fort Lauderdale, FL.
Objective: To evaluate effects of maternal HIV and antiretroviral treatment (ART) on intrauterine fetal growth.
Design: Prospective cohort studies of HIV and ZIKA infection among women living with HIV (WLHIV) and women not living with HIV (WNLHIV) conducted in Brazil and the US from 2016 to 2020.
Methods: We evaluated fetal growth via repeated ultrasounds and calculated z scores for fetal growth measures using Intergrowth-21st standards among women with singleton pregnancies.
Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
HIV Med
January 2024
Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Introduction: The effect of antiretroviral therapy (ART), particularly integrase strand transfer inhibitors (INSTIs), on non-alcoholic fatty liver disease (NAFLD) in people with HIV remains unclear. We evaluated the effect of switching non-INSTI backbone antiretroviral medications to raltegravir on NAFLD and metabolic parameters.
Materials And Methods: This was a single-centre, phase IV, open-label, randomized controlled clinical trial.
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
PLoS One
September 2022
Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America.
Objective: To assess in ART-naïve pregnant women randomized to efavirenz- versus raltegravir-based ART (IMPAACT P1081) whether pretreatment drug resistance (PDR) with minority frequency variants (<20% of individual's viral quasispecies) affects antiretroviral treatment (ART)-suppression at term.
Design: A case-control study design compared PDR minority variants in cases with virologic non-suppression (plasma HIV RNA >200 copies/mL) at delivery to randomly selected ART-suppressed controls.
Methods: HIV pol genotypes were derived from pretreatment plasma specimens by Illumina sequencing.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!